Eli Lilly gene therapy allows child born deaf to hear, clinical trial shows

An Eli Lilly & Co. LLY, -0.50% experimental gene therapy has restored the hearing of a child who was born deaf, the pharmaceutical giant said Tuesday. The child, who was 11 years old at the time the therapy was administered, experienced restored hearing within 30 days of treatment, Eli Lilly said in a release. The child participating in the clinical study was the first individual in the U.S. to receive the therapy for a genetic form of hearing loss, the company said. The gene therapy, AK-OTOF, is being deve ...